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A B S T R A C T
Introduction: Korean herbal medicine (KHM) is widely used as a therapeutic modality during pregnancy
in Korea. The purpose of this review is to identify use and adverse events (AEs) associated with KHM
during pregnancy in Korean medicine literature.
Methods: We searched Pubmed, EMBASE, Cumulative Index to Nursing and Allied Health Literature
(CINAHL) and ﬁve Korean databases to identify relevant studies published before January 2015. Studies
were included regardless of their design if they reported original data and involved KHM for any
conditions in pregnant women. For safety problems, we also excluded studies if there was no information
about maternal and fetal outcomes.
Results: Fifty-two studies were included in this review. The most frequently reported indication for KHM
was hyperemesis gravidarum (26.3%). Anjeonicheon-tang and Atractylodes Rhizome White were the
most commonly used in KHM prescriptions and as single herbs during pregnancy. Some studies reported
mild or unassessable AEs like diarrhea, pruritis, and preterm birth. Severe AEs were all considered
unlikely to have been caused by KHM.
Conclusions: Hyperemesis gravidarum and maintaining pregnancy accounted for more than two-thirds of
clinical indications for KHM during pregnancy in Korean medicine literature. Few studies reported on
mild AEs associated with KHM, but due to a lack of large prospective surveys, this ﬁnding is not
conclusive. Prospective studies with a larger sample size are needed to conﬁrm the safety of KHM during
pregnancy.
ã 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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An increasing number of women worldwide use complemen-
tary and alternative medicine, usually regarded as being natural
and safe, to treat illness during pregnancy [1]. Korean herbal
medicines (KHM) are used for pregnancy-related indications such
as threatened miscarriage, hyperemesis gravidarum, or recurrent
miscarriages in Korea [2].
Both traditional medicines and western medicines have the
potential to cause adverse pregnancy outcomes and affect embry-
onicandfetal development inpregnant women [3]. However, it isnot
ethical to test the adverse effects and toxicity of medicines in human
subjects. Therefore, animal studies can provide important data on
the potential toxicity of medicines. Two recent experimental studies
about the safety of those commonly used Chinese medicine (CM)
during pregnancy showed that adverse pregnancy outcomes were
common, suggesting CM could do harm during pregnancy [4,5]. But,
those studies were criticized because of inconsistencies, implausi-
bilities and several severe biometrical ﬂaws [6].
A recent systematic review on adverse outcomes of CM for
threatened miscarriage pooled data from clinically very heteroge-
neous studies, and found adverse events (AEs) like dry mouth,
constipation, insomnia, diabetic complications, preterm delivery
and neurodevelopmental morbidity [7]. Meta-analysis demon-
strated no signiﬁcant differences between combined CM group and
western medicines group for AEs and toxicity or for adverse
maternal and fetal outcomes [7].
KHM shares its origins with CM and has been historically
utilized as safe during pregnancy. However, there is insufﬁcient
data regarding the use and safety of using KHM during pregnancy.
The aim of this study was (i) to identify the commonly used KHM
prescriptions and single medicines during pregnancy; (ii) to
analyze the adverse outcomes of KHM during pregnancy.
2. Materials and methods
2.1. Search strategy
We searched electronic databases for relevant studies pub-
lished before January 2015, including Pubmed, EMBASE, Cumula-
tive Index to Nursing and Allied Health Literature (CINAHL) and
ﬁve Korean databases: the Korean Studies Information Service
System (http://kiss.kstudy.com/), KoreaMed (http://www.kore-
amed.org), Oriental Medicine Advanced Searching Integrated
System (http://oasis.kiom.re.kr), The Journal of Korean Obstetrics
and Gynecology (http://oobgy.or.kr/) and The Journal of KoreanMedicine (http://www.jkom.org/). The following search terms
were used: “Korean herbal medicine”, “traditional Korean medi-
cine”, “miscarriage”, “adverse events”, and “pregnancy”.
2.2. Study selection
To identify use, we included all types of studies if they involved
pregnant women treated for any conditions by KHM prescribed by
a Korean Medicine physician. For safety questions, the only studies
included were those with documented pregnancy outcomes. We
excluded studies if there was no information provided about the
medicines used or the number of patients treated with KHM. There
was no restriction to the type of studies.
2.3. Data extraction and analysis
We analyzed the prescriptions in each study and counted
medicines in the prescriptions. We summed the prescriptions and
single medicines from all relevant studies. For the safety question,
the sum was the number of documented cases for which data
about a pregnancy outcome were available. At least 100 docu-
mented cases demonstrating pregnancy outcomes was rated as
preliminary evidence of safety [6].
Two authors (JJ and SHL) extracted data regarding author(s),
publication year, study design, sample size, gestational week,
purpose for KHM, duration of KHM and detailed information on
AEs. AEs were classiﬁed into maternal and neonatal outcomes.
The severity of each AE was graded 1 (mild) to 3 (severe)
according to modiﬁed Spilker’s AE classiﬁcation [8,9]. It was
determined as mild if the AE had no impact on ability to perform
normal delivery, such as diarrhea, headache, and hyperemesis
gravidarum. Moderate was deﬁned if AE could impact on delivery
with some problems, such as preterm birth. Severe AE is a death of
an embryo or fetus, such as spontaneous abortion. Causality – that
is, the strength of the relationship between AEs and KHM – was
assessed by two reviewers (SHL, paediatrics of Korean Medicine
specialist and JJ, obstetrics/gynaecology of Korean Medicine
specialist) in accordance with the causality categories in the
World Health Organisation–Uppsala Monitoring Centre (WHO–
UMC) system for standardised case causality assessment [10]. The
causality categories used were certain, probable/likely, possible,
unlikely, conditional/unclassiﬁed and unassessable/unclassiﬁable.
The incidence of AEs was presented as the number of cases per
number of KHM treated participants (%).
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3.1. Identiﬁcation of articles
Three hundred and eighteen publications about KHM taken
during pregnancy were identiﬁed from the database search. After
duplicates were removed, 222 records were screened by the titles
and abstracts and 168 articles were excluded. The full texts of the
remaining 54 studies were assessed for study eligibility. Finally,
52 studies were included for review. There were eight retrospec-
tive studies, 24 case reports and 20 case series. Pregnancy
outcomes or neonatal outcomes were not reported in 23 studies.
Twenty-nine studies (395 women) were reviewed for safety issue.
There were no randomized controlled trials (RCTs), 17 case reports
and 12 case series (Fig. 1). The detailed information of 52 studies
are provided in an online supplementary table.
3.2. Commonly used KHM prescriptions and single medicines
3.2.1. Clinical applications of KHM commonly used during pregnancy
in Korean medicine literature
Amongst all literature reporting KHM used during pregnancy,
hyperemesis gravidarum (26.3%) was the most common clinical
indication for KHM (Fig. 2) [11–30]. Less common, clinical
indications included recurrent pregnancy loss (16.5%)
[12,23,31,32], threatened miscarriage (12.7%) [12,23,27,28,33,34],
preventing miscarriage (11.7%) [12,23,35–39], common cold (6.7%)
[12,14,17,21,23,27,40], safe delivery (5.2%) [12,21,23,27,28], facial
palsy (3.4%) [41–46], lumbago (2.1%) [12,14,47,48], and other
obstetric complications (15.3%) (Fig. 2) [12,22,39,49–62].
3.2.2. Number of cases of commonly used prescriptions in Korean
medicine literature
Amongst all the prescriptions studied during pregnancy,
“Anjeonicheon-tang” was the most frequently used formula
(29.5%) (Table 1). “Anjeonicheon-tang” is prescribed mostly for
recurrent miscarriage and relieves clinical signs such as vaginal
bleeding [63]. Other popular prescriptions include “Bosaeng-tang”,318 records ident ifi ed 
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Fig. 1. Flow diagram o“Dangkwi-san” and “Gyullyeongbosaeng-tang”. These three pre-
scriptions are usually used to relieve hyperemesis gravidarum. The
compositions of most commonly studied Korean medicines during
pregnancy are documented in Table 1.
3.2.3. Single KHMs used in pregnancy with at least 100 documented
cases in Korean medicine literature
The single KHM for at least 100 documented cases in Korean
medicine literature included Atractylodis Rhizoma White (81.6%),
Glycyrrhizae Radix (81.4%), Ginseng Radix (62.1%), Citri Peri-
carpium (54.1%), Amomi Fructus (51.0%), Rehmanniae Radix
Preparata (47.1%), Scutellariae Radix (43.4%), Cyperi Rhizoma
(41.6%), Eucommiae Cortex (39.5%), Perilla Herba (38.3%), Paeoniae
Radix Alba (38.3%), Angelicae Gigantis Radix (37.7%), Cnidii
Rhizoma (35.4%), Lycii Fructus (35.0%), Dioscoreae Rhizoma
(34.0%), Poria (33.8%), Zingiberis Rhizoma Crudus (32.6%), Corni
Fructus (28.5%), Dolichoris Semen (26.6%), Amomi Fructus
Rotundus (23.2%), and Aurantii Fructus (19.7%) in descending
order (Table 2).
3.3. KHM prescription and single medicines reporting maternal or
neonatal outcomes
3.3.1. Number of cases for which prescriptions were used and reported
maternal or neonatal outcomes
“Anjeonicheon-tang” was also the most frequently used
formula (33.4%) (Table 1). Bosaeng-tang, Dangkwi-san, Antae-
eum, Gungso-san, Gyoaesamul-tang, Dalsaeng-san, and Antae-
geumchul-tang were also in the frequent remedies of KHM
prescribed to pregnant women (Table 1).
3.3.2. Single KHM with at least 100 documented cases which reported
maternal or neonatal outcomes
Single KHM with at least 100 documented cases in Korean
medicine literature included Atractylodis Rhizoma White (86.6%),
Glycyrrhizae Radix (86.1%), Ginseng Radix (68.1%), Rehmanniae
Radix Preparata (55.3%), Citri Pericarpium (50.9%), Amomi Fructus
(48.6%), Eucommiae Cortex (46.0%), Scutellariae Radix (43.7%),uplicates  removed
excluded
 not herbal  medicine during pregnancy 
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Fig. 2. Clinical applications of KHM commonly used during pregnancy in Korean medicine literature.
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Alba (39.3%), Angelicae Gigantis Radix (39.1%), Cyperi Rhizoma
(39.1%), Perilla Herba (38.6%), Corni Fructus (36.0%), Cnidii
Rhizoma (35.7%), Dolichoris Semen (34.2%), Poria (28.3%), and
Zingiberis Rhizoma Crudus (27.5%) in descending order (Table 3).
Rehmanniae Radix Preparata was used by the largest mean doses
(19.55 g/day) and maximum dose (30.0 g/day).
3.4. Adverse events
We identiﬁed a total of 65 AEs from 52 cases in the 10 reports
(Tables 4 and 5). When AEs were graded according to modiﬁed
Spilker’s AE classiﬁcation and WHO-UMC causality assessment,
mild AEs (n = 3) occurred in 2 cases with 2 certain and 1
unassessable causality. Moderate AEs (n = 24) occurred in 12 cases
with 19 unlikely and 5 unassessable causality. Severe AEs (n = 38)
were all considered unlikely to have been caused by KHMTable 1
Compositions of most commonly used Korean herbal medicines during pregnancy.
Korean medicine
formulae
Usea Use reported
pregnancy outcomea
Compositions and dail
Anjeonicheon-tang 151 (29.5%) 132 (33.4%) Atractylodis Rhizoma W
Dioscoreae Rhizoma 13
2.67
Bosaeng-tang 68 (13.3%) 44 (11.1%) Atractylodis Rhizoma W
Glycyrrhizae Radix 7.5
Dangkwi-san 47 (9.2%) 37 (9.4%) Angelicae Gigantis Rad
Rhizoma White 1.67
Antae-eum 41 (8.0%) 23 (5.8%) Angelicae Gigantis Rad
Pericarpium, Cnidii Rh
Scutellariae Radix 2.25
Gyullyeongbosaeng-
tang
40 (7.8%) – Citri Pericarpium 18.75
Katsumadai Semen, Po
Rhizoma Crudus 10 pie
Gungso-san 36 (7.0%) 31 (7.8%) Liriopis Tuber, Peuceda
Cnidii Rhizoma, Paeon
Gyoaesamul-tang 25 (4.9%) 24 (6.1%) Amomi Fructus, Angeli
White, Cnidii Rhizoma
Radix 7.5
Dalsaeng-san 19 (3.7%) 19 (4.8%) Arecae Pericarpium 15
Paeoniae Radix Alba 7.5
3.75
Antaegeumchul-
tang
16 (3.1%) 15 (3.8%) Terba Flava Usta 24, At
Citri Pericarpium, Cype
Perilla Herba 6, Auckla
Radix 4
Ondam-tang 13 (2.5%) – Aurantii Immaturus Fr
Zingiberis Rhizoma Cru
Samul-tang – 10 (2.5%) Angelicae Gigantis Rad
Palmul-tang – 8 (2.0%) Angelicae Gigantis Rad
Radix, Paeoniae Radix 
a % is the number of cases of each prescription/total amount of cases  100.prescriptions. Detailed AEs associated with KHM prescriptions
are summarised in Tables 4 and 5. The AE incidence of KHM with
certain or unassessable causality was 1.5%, and limiting the
calculation to AEs evaluated as certain in the causality assessment
resulted in an incidence of 0.3%.
3.4.1. Adverse maternal outcomes
Five hundred and twelve women took KHM during pregnancy,
but the pregnancy outcome was only available for 395 women.
Among 395 women, 343 women had normal deliveries (86.8%),
11 women had preterm deliveries (2.8%), 3 women had preterm or
postmature delivery (0.8%), and 38 women had miscarriages
(9.6%). Most miscarriages were from threatened miscarriage and
recurrent pregnancy loss patients [12,14,21,23,36]. Mild or
unassessable AEs such as diarrhea, pruritus, or preterm birth
were reported in one case report [50] and 4 retrospective studies
[11,12,17,23].y dose (g)
hite, Ginseng Radix, Rehmanniae Radix Preparata 26.67, Corni Fructus,
.33, Eucommiae Cortex 8, Dolichoris Semen, Lycii Fructus 5.33, Glycyrrhizae Radix
hite, Citri Pericarpium, Cyperi Rhizoma, Linderae Radix 15, Ginseng Radix,
ix, Cnidii Rhizoma, Paeoniae Radix Alba, Scutellariae Radix 3.33, Atractylodis
ix, Atractylodis Rhizoma White, Paeoniae Radix, Rehmanniae Radix 7.5, Citri
izoma, Ginseng Radix 3.75, Amomi Fructus, Glycyrrhizae Radix, Perilla Herba,
, Amomi Fructus, Atractylodis Rhizoma White, Cyperi Rhizoma, Poria 7.5 Alpiniae
gostemonis Herba, Scutellariae Radix 5.25 Glycyrrhizae Radix 3.75, Zingiberis
ces, Mume Fructus 2 pieces
ni Radix, Scutellariae Radix 7.5, Atractylodis Rhizoma White, Citri Pericarpium,
iae Radix Alba 6, Perilla Herba 4.5, Pueraiae Radix 3.75, Glycyrrhizae Radix 2.25
cae Gigantis Radix, Artemisiae Argi Folium, Asini Gelatinum, Atractylodis Rhizoma
, Cyperi Rhizoma, Paeoniae Radix Alba, Rehmanniae Radix Preparata, Scutellariae
, Glycyrrhizae Radix 11.25, Angelicae Gigantis Radix, Atractylodis Rhizoma White,
, Amomi Fructus, Aurantii Fructus, Citri Pericarpium, Ginseng Radix, Perilla Herba
ractylodis Rhizoma White 16, Pinelliae Rhizoma, Zingiberis Rhizoma Crudus 12,
ri Rhizoma, Poria, Scutellariae Radix 8, Amomi Fructus, Amomi Rotundus Fructus,
ndiae Radix, Aurantii Fructus, Citri Reticulatae Viride Pericarpium, Glycyrrhizae
uctus, Citri Pericarpium, Pinelliae Rhizoma 7.5, Poria 4.13, Glycyrrhizae Radix 3,
dus 14 pieces, Jujubae Fructus 2 pieces, Bambusae Caulus in Taeniam 2 pieces
ix, Cnidii Rhizoma, Paeoniae Radix Alba, Rehmanniae Radix Preparata 9.38
ix, Atractylodis Rhizoma White, Cnidii Rhizoma, Ginseng Radix, Glycyrrhizae
Alba, Poria, Rehmanniae Radix Preparata 9
Table 2
Number of cases on which single medicinal herb was used in Korean medicine
literature during pregnancy.
Scientiﬁc names (Biological names) Totala (%)
Atractylodis Rhizoma White (Atractylodes japonica) 418 (81.6%)
Glycyrrhizae Radix (Glycyrrhiza glabra) 417 (81.4%)
Ginseng Radix (Panax ginseng) 318 (62.1%)
Citri Pericarpium (Citrus unshiu) 277 (54.1%)
Amomi Fructus (Amomum villosum) 261 (51.0%)
Rehmanniae Radix Preparata (Rehmannia glutinosa) 241 (47.1%)
Scutellariae Radix (Scutellaria baicalensis) 222 (43.4%)
Cyperi Rhizoma (Cyperus rotundus) 213 (41.6%)
Perilla Herba (Perilla frutescens) 202 (39.5%)
Eucommiae Cortex (Eucommia ulmoides) 196 (38.3%)
Paeoniae Radix Alba (Paeonia lactiﬂora) 196 (38.3%)
Angelicae Gigantis Radix (Angelica gigas) 193 (37.7%)
Cnidii Rhizona (Cnidium ofﬁcinale) 181 (35.4%)
Lycii Fructus (Lycium chinense) 179 (35.0%)
Dioscoreae Rhizoma (Dioscorea batatas) 174 (34.0%)
Poria (Poria cocos) 173 (33.8%)
Zingiberis Rhizoma Crudus (Zingiber ofﬁcinale) 167 (32.6%)
Corni fructus (Cornus ofﬁcinalis) 146 (28.5%)
Dolichoris Semen (Dolichos lablab) 136 (26.6%)
Amomi Fructus Rotundus (Amomum krabanh) 119 (23.2%)
Aurantii Fructus (Citrus aurantium) 101 (19.7%)
a 512 cases.
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One neonatal jaundice [39], three very low birth weight infants
[11,12] and ﬁve low birth weight infants [12,17] were reported due
to preterm delivery. One fetal macrosomia was reported due to
gestational diabetes [12]. Also, one hypoxia and hypoglycemia [17]
and one patent ductus arteriosus [12] infants were reported among
low birth weight infants due to preterm delivery. The status of the
remaining two infants out of the 11 preterm deliveries was not
documented [23,62].
4. Discussion
In this review, we found that hyperemesis gravidarum was the
most common clinical indication of KHM and Anjeonicheon-tang
was the most frequently used formula. We also analyzed the
prescriptions and tabulated use of single herb medicines that
documented at least 100 cases in Korean medicine literature.
Atractylodis Rhizoma White was the most common single herb
during pregnancy. We identiﬁed the adverse maternal andTable 3
Doses and number of cases of single KHM used in studies reporting mater
Scientiﬁc names (Biological names) 
Atractylodis Rhizoma White (Atractylodes japonica) 
Glycyrrhizae Radix (Glycyrrhiza glabra) 
Ginseng Radix (Panax ginseng) 
Rehmanniae Radix Preparata (Rehmannia glutinosa) 
Citri Pericarpium (Citrus unshiu) 
Amomi Fructus (Amomum villosum) 
Eucommiae Cortex (Eucommia ulmoides) 
Scutellariae Radix (Scutellaria baicalensis) 
Dioscoreae Rhizoma (Dioscorea batatas) 
Lycii Fructus (Lycium chinense) 
Cyperi Rhizoma (Cyperus rotundus) 
Perilla Herba (Perilla frutescens) 
Angelicae Gigantis Radix (Angelica gigas) 
Paeoniae Radix Alba (Paeonia lactiﬂora) 
Cnidii Rhizoma (Cnidium ofﬁcinale) 
Corni Fructus (Cornus ofﬁcinalis) 
Dolichoris Semen (Dolichos lablab) 
Poria (Poria cocos) 
Zingiberis Rhizoma Crudus (Zingiber ofﬁcinale) 
a Dose are presented as mean  SD (min–max) per day.
b Total cases were 395 cases.neonatal outcomes associated with KHM during pregnancy were
rarely reported in most studies, and reported AEs were evaluated
as mild in severity or had unassessable or unlikely causalities.
Therefore, there was limited evidence for us to ﬁnd a direct relation
between the adverse maternal outcomes with KHM.
Anjeonicheon-tang has been applied for threatened miscar-
riages or supporting implantation by tonifying “innate qi” and
“acquired qi” [36,64]. Amongst all the formulae studied for
threatened miscarriage in CM, “Anjeonicheon-tang” was the ﬁfth
frequently used formula [63]. Antae-eum which was fourth
frequently used decoction in this review was third frequently
used decoction amongst all the formulae studied for threatened
miscarriage in CM [63]. Other decoctions did not overlap between
the two reviews. These discrepancies might come from the
differences of indication of herbal medicine used for threatened
miscarriage in CM and for all indications during pregnancy in KHM.
Also, the reports on KHM during pregnancy mostly came from one
hospital.
There is a lack of appropriate information regarding AEs in
speciﬁc CM as well as speciﬁc KHM. Therefore, it may be difﬁcult
to make any meaningful comparisons of AEs between these two
countries. Antae-eum was related with diarrhea in patient with
preterm labor [50] and preterm birth in patient with pre-
eclampsia [62], but other eight studies reported no AEs
[13,26,31,34,43,45,47,53]. Such results are in line with CM review
on threatened miscarriage [7] which reported 0.7% of preterm
delivery, 0.7% of neonatal death due to prematurity, and 0.3% of
epilepsy. Comparisons of AEs of other decoctions were not
feasible due to lack of data.
Atractylodis Rhizoma White is one herb of Antae-eum which is
highly recommended to beneﬁt and help the fetus survive by
improving the function of “kidney” and regulating “Qi” and “blood”
[63]. Atractylodis Rhizoma White is also the most commonly used
CM for threatened miscarriage [5]. Recent animal studies reported
that Atractylodis Rhizoma White affects limb development by
suppressing the expression of limb developmental genes and
disturbing programmed cell death during limb formation in mice
[5]. Potential reproductive toxicity of Atractylodis Rhizoma White
in pregnant animals was identiﬁed within the clinical dose range
[65]. However, there was no toxicity identiﬁed in our review
including more than 300 cases of Atractylodis Rhizoma White.
Reproductive toxicities of CM commonly used during pregnan-
cy such as Atractylodis Rhizoma White, Scutellariae Radix,nal or perinatal outcome.
Dosea (g) Cases (%)b
19.07  7.15 (5.63–26.67) 348 (88.1)
5.29  2.85 (2.25–12.00) 346 (87.6)
17.29  10.20 (3.75–26.67) 273 (69.1)
19.54  9.42 (5.71–30.00) 217 (54.9)
9.26  4.35 (3.75–18.75) 209 (52.9)
6.65  1.67 (2.25–12.00) 200 (50.6)
7.66  1.11 (5.71–12.00) 179 (45.3)
6.83  2.71 (1.43–16.00) 175 (44.3)
13.16  1.71 (3.75–16.00) 169 (42.8)
5.60  2.16 (5.33–24.00) 167 (42.3)
9.34  3.68 (5.71–16.00) 161 (40.8)
5.95  2.67 (2.25–12.00) 161 (40.8)
8.19  2.08 (3.75–16.00) 155 (39.2)
8.23  2.39 (5.71–18.75) 155 (39.2)
7.50  2.29 (3.75–16.00) 141 (35.7)
13.38  1.29 (8.00–22.50) 141 (35.7)
5.33 133 (33.7)
7.56  2.24 (4.00–16.00) 120 (30.4)
13.10  7.50 (6.00–28.57) 110 (27.8)
Table 4
Adverse maternal outcomes associated with KHM prescriptions.
RN Author
(year)
Agea (years) Maternal
herbal
prescription
Concomitant treatment Herbal medicine use Maternal AEs
Purpose
(diagnosis)
Duration
(day)
Occurs Severity Causality
[11] Ahn et al
(2014)
28–38 (31.37) Multiple NS HA 5–25 1 SA Severe Unlikely
1 IA from maternal disease Severe Unlikely
1 Preterm birth Moderate Unassessable
[12] Jung et al
(2014)
(32  4.3) Multiple Antihistamine (Pruritis
gravidarum), Surgery
(Cervical incompetency,
Intestinal obstruction,
Ovarian cancer)
Multiple 2–28 3 SA Severe Unlikely
1 Gestational diabetes Moderate Unlikely
1 Pruritus gravidarum Mild Unassessable
1 Preterm birth from
premature rupture of
membranes
Moderate Unassessable
3 Preterm birth from
surgery
Moderate Unlikely
[62] Kim et al
(2013)
40 ATE Acup Pre-eclampsia 43 Preterm birth from pre-
eclampsia
Moderate Unlikely
[50] Jo et al
(2012)
33 DKJYS NS Abdominal pain 7 Diarrhea Mild Certain
ATE Progesterone Preterm labor 10 Diarrhea Mild Certain
[36] Lee et al
(2010)
NS AJICT WM(partially) Preventing
miscarriage
1.73  1.26
months
10 SA Severe Unlikely
[14] Jo et al
(2008)
22–35
(29.7  3.4)
Multiple NS Multiple 4–40 1 SA Severe Unlikely
[17] Choi et al
(2005)
(29.8  4.70) Multiple NS Multiple 3–47 3 SA Severe Unlikely
1 IA from r/o Down
syndrome
Severe Unlikely
1 Gestational diabetes &
Preterm birth from
premature rupture of
membrane
Moderate Unlikely
1 Preterm birth from
preterm labor
Moderate Unassessable
1 preterm birth from twins Moderate Unlikely
[39] Zhang et al
(2004)
37 PMT None Preventing
miscarriage
(1 Fetal death in
utero of twins)
7 Preterm birth from fetal
death in utero
Moderate Unlikely
[21] Kim et al
(2003)
(30.06  3.73) Multiple NS Multiple 2–40 2 SA Severe Unlikely
1 IA from severe HA Severe Unlikely
[23] Heo et al
(2002)
NS Multiple NS Multiple NS 1 preterm birth Moderate Unassessable
Recurrent
pregnancy loss
10 abortion Severe Unlikely
Threatened
abortion
5 abortion Severe Unlikely
Multiple: Details of the “Multiple” are provided in Supplementary data. RN: reference number, AEs: adverse events, NS: Non-speciﬁc, ATE: Antae-eum, DKJYS:
Dangkwijagyak-san, AJICT: Anjeonicheon-tang, HSPWS: Hyangsapyeongwi-san, PMT: Palmul-tang, BCS: Banchong-san, CJHBH: Chiljehyangbu-hwan, DKS: dangkwi-san, BST:
Bosaeng-tang, WM: Western medicine, Acup: Acupuncture, Moxa: Moxibustion, HA: Hyperemesis gravidarum, SA: Spontaneous abortion, IA: Induced abortion.
a (Mean  standard deviation).
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Glycyrrhizae Radix, Dioscoreae Rhizoma, and Amomi Fructus were
identiﬁed in mice [4], but these animal studies includes many
inconsistencies, implausibilities and several severe biometrical
ﬂaws [6]. The evidence regarding the use of CM for threatened
miscarriage on adverse effects/toxicity, and adverse maternal and
fetal outcomes, is limited, but the review suggest that CM for
threatened miscarriage may not be associated with increased risk
of preterm delivery, neonatal mortality and congenital malforma-
tion. Our results are in line with these results. The prevalence of
birth defects was 286.9 per 10,000 livebirths in 2005–2006 in
Korea [66], but only two birth defects including one patent ductus
arteriosus, and one hypoxia and hypoglycemia were identiﬁed in
354 babies in our review, as opposed to 10 expected.
Those medicines with higher case numbers (over 100 cases) in
our review suggest that a preliminary positive safety statement is
warranted. Also, it seems that they had no severe AEs with certain
or possible causality. Atractylodis Rhizoma White, Glycyrrhizae
Radix, Eucommiae Cortex, Dioscoreae Rhizoma, Paeoniae RadixAlba, Angelicae Gigantis Radix, Amomi Fructus are considered safe
with regard to fetal growth or birth weight [6]. Using these herbs
below reported maximum daily dose (Table 3) result in side effects
only rarely to pregnant women and fetus.
5. Limitation
We tried to conduct comprehensive electronic database search
but, we cannot rule out that we might have missed some relevant
articles or unpublished data. Most studies did not evaluate AEs as
study outcome assessment. It may be because the occurrence of
AEs was indeed too rare or because awareness of the AEs was
actually too low, as in the CM review [7]. There were no RCTs, and
all studies are case reports and case series without controls that
were retrospectively studied. The sample sizes of the studies were
very small. To detect teratogenicity, a large epidemiological study
is needed [6]. Therefore, we could not draw a ﬁrm conclusion of the
safety of KHM during pregnancy. More studies with rigorous
designs to assess the safety are needed.
Table 5
Adverse neonatal outcomes associated with KHM prescriptions.
RN Author
(year)
Agea (mean) Maternal herbal
prescription
Concomitant treatment Herbal medicine use Neonatal AEs
Purpose
(Diagnosis)
Duration
(day)
Occurs Severity Causality
[11] Ahn et al
(2014)
28–38
(31.37)
Multiple NS Hyperemesis
gravidarum
5–25 1 Very low birth
weight infant
Moderate Unassessable
[12] Jung et al
(2014)
(32  4.3) Multiple Antihistamine (Pruritis
gravidarum), Surgery
(Cervical incompetency,
Intestinal obstruction,
Ovarian cancer)
Multiple 2–28 2 Low birth weight
infant
Moderate Unlikely
2 Very low birth
weight infant
Moderate Unlikely
1 Fetal macrosomia Moderate Unlikely
1 Patent ductus
arteriosus
Moderate Unlikely
[17] Choi et al
(2005)
(29.8  4.70) Multiple NS Multiple 3–47 3 Low birth weight
infant
Moderate Unlikely
1Hypoxia and
hypoglycemia
Moderate Unlikely
[39] Zhang et al
(2004)
37 PMT None Preventing
miscarriage (Fetal
death in utero)
7 Neonatal jaundice Moderate Unlikely
a (Mean  standard deviation). Multiple: Details of the “Multiple” are provided in Supplementary data. RN: reference number, AE: adverse event, NS: Non-speciﬁc, WM:
Western medicine, Acup: Acupuncture, Moxa: Moxibustion, PMT: Palmul-tang.
10 J. Jo et al. / European Journal of Integrative Medicine 8 (2016) 4–116. Conclusion
We found that hyperemesis gravidarum was the most common
clinical indication of KHM and Anjeonicheon-tang was the most
frequently used formula in Korean medicine literature. Atracty-
lodis Rhizoma White was the most common single herb used
during pregnancy in Korean medicine literature. Few studies
reported on mild AEs associated with KHM, but due to a lack of
large prospective surveys, the question is still open. Prospective
studies with a larger sample size are needed to conﬁrm the safety
of KHM during pregnancy.
Conﬂict of interests
All authors declare that they have no conﬂict of interests.
Acknowledgments
This study was supported by the Association of Korean
Medicine and Korean Academy of Breastfeeding Medicine.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.eujim.
2015.10.008.
References
[1] H.Y. Yeh, Y.C. Chen, F.P. Chen, L.F. Chou, T.J. Chen, S.J. Hwang, Use of traditional
Chinese medicine among pregnant women in Taiwan, Int. J. Gynaecol.
Obstetrics Off. Organ Int. Fed. Gynaecol. Obstetrics 107 (2009) 147–150.
[2] H. Lee, Y. Kim, E. Lim, Analysis for 23 studies of patients that used herbal
medicine during pregnancy, J. Korean Obstet. Gynecol. 20 (2007) 185–199.
[3] C.C. Wang, L. Li, C.B. San Lau, P.C. Leung, K.P. Fung, Pregnancy outcomes,
embryonic and fetal development in maternal exposure to Chinese medicines,
Birth Defects Res. C Embryo Today 99 (2013) 275–291.
[4] C.C. Wang, L. Li, L.Y. Tang, P.C. Leung, Safety evaluation of commonly used
Chinese herbal medicines during pregnancy in mice, Hum. Reprod. 27 (2012)
2448–2456.
[5] L.Y. Tang, L. Li, A. Borchert, C.B. Lau, P.C. Leung, C.C. Wang, Molecular studies of
the congenital malformation induced by Largehead Atractylodes Rhizome, the
most commonly used Chinese medicine for threatened miscarriage, Mol. Hum.
Reprod. 18 (2012) 585–592.
[6] A. Wiebrecht, W. Gaus, S. Becker, J. Hummelsberger, K. Kuhlmann, Safety
aspects of Chinese herbal medicine in pregnancy—Re-evaluation ofexperimental data of two animal studies and the clinical experience,
Complementary Ther. Med. 22 (2014) 954–964.
[7] L. Li, L.X. Dou, J.P. Neilson, P.C. Leung, C.C. Wang, Adverse outcomes of Chinese
medicines used for threatened miscarriage: a systematic review and meta-
analysis, Hum. Reprod. Update 18 (2012) 504–524.
[8] D.W. Raisch, W.G. Troutman, M.R. Sather, P.J. Fudala, Variability in the
assessment of adverse events in a multicenter clinical trial, Clin. Ther. 23
(2001) 2011–2020.
[9] B. Spilker, Guide to Clinical Trials, Raven Press, New York, 1991.
[10] World Health Organization (WHO)–Uppsala Monitoring Centre. The use of the
WHO–UMC system for standardized case causality assessment. 2012.
[11] I.S. Ahn, D.I. Kim, M.S. Choi, S.H. Kim, The Analysis of delivery outcomes in
cases of hyperemesis gravidarum patients medicated with Pinelliae Rhizoma –
to establish a guideline in administration of Pinelliae Rhizoma, J. Korean
Obstet. Gynecol. 27 (2014) 94–103.
[12] E.H. Jung, S.B. Jang, K.H. Choi, D.Y. Yoo, A retrospective study of patients that
used Herbal Medicine during pregnancy, J. Korean Obstet. Gynecol. 27 (2014)
79–93.
[13] J.Y. Ok, I.S. Lee, H.S. Cho, A clinical study of hyperemesis patient treated oriental
medicine, J. Korean Obstet. Gynecol. 25 (2012) 116–124.
[14] H.J. Jo, H.J. Gu, S.J. Yang, K.M. Park, S.H. Cho, H.H. Lee, et al., A clinical analysis of
patients that used herbal medicine during pregnancy for medical treatment, J.
Korean Obstet. Gynecol. 21 (2008) 150–158.
[15] Y.K. Yoo, J.A. Lee, H.J. Kim, D.N. Lee, A case report of urinary infection in
hyperemesis gravidarum, J. Korean Obstet. Gynecol. 21 (2008) 276–285.
[16] Y.K. Yoo, S.J. Bae, H.J. Kim, D.N. Lee, A case report of complaining of disturbed
liver function in hyperemesis gravidarum, J. Korean Obstet. Gynecol. 19 (2006)
279–286.
[17] M.S. Choi, D.I. Kim, A clinical analysis of patients that used herbal medicine in
pregnancy and retrospective survey of patient’s treatment satisfaction, J.
Korean Obstet. Gynecol. 18 (2005) 127–138.
[18] S.J. Kim, D.C. Kim, S.H. Baek, Clinical study for the two cases complaining
hyperemesis with vaginal bleeding or abdominal pain after IVF, J. Korean
Obstet. Gynecol. 18 (2005) 176–185.
[19] J.S. Park, E.M. Lim, A case report of 1 patient complaining of hyperemesis
gravidarium, J. Korean Obstet. Gynecol. 18 (2005) 234–241.
[20] J.W. Heo, J.H. Cho, J.B. Jang, K.S. Lee, The three case on the effect of oriental
medical treatment of hyperemesis gravidum, J. Korean Obstet. Gynecol. 17
(2004) 171–178.
[21] Y.G. Kim, D.C. Kim, S.H. Baek, A clinical analysis of 50 fetus that using herbal
medication during pregnancy, J. Korean Obstet. Gynecol. 16 (2003) 136–143.
[22] Y.W. Shin, J.E. Lee, B.R. Lee, K.S. Shin, J.H. Jeong, D.Y. Yoo, Clinical study on seven
case of diseases and complications of pregnancy with Kami-Dangkwi-San, J.
Korean Obstet. Gynecol. 16 (2003) 180–188.
[23] J.W. Heo, J.H. Cho, J.B. Jang, K.S. Lee, The clinical analysis of 146 patients that
using herbal medication during pregnancy at Conmaul Oriental Hospital, J.
Korean Obstet. Gynecol. 15 (2002) 129–138.
[24] T.H. Kim, C.M. Choi, S.E. Hong, J.J. Lee, S.K. Yoo, Clinical study for the 20 cases of
the hyperemesis patients prescribed Kakambosengtang who have weakness of
the spleen and stomach, J. Korean Obstet. Gynecol. 15 (2002) 128–138.
[25] S.J. Yang, S.H. Cho, C.S. Jin, Clinical study for the 8 cases of the hyperemesis
patients, J. Korean Obstet. Gynecol. 15 (2002) 190–199.
[26] K.M. Park, J.H. Jeong, D.Y. Yoo, Clinical Study on 1 case of the lumbago patient
during pregnancy with pernicious vomiting, J. Korean Obstet. Gynecol. 14
(2001) 199–208.
J. Jo et al. / European Journal of Integrative Medicine 8 (2016) 4–11 11[27] I.H. Yi, I.J. Kim, J.B. Jang, B.K. Song, K.S. Lee, A clinical study on the effects of
Herbal Medicine on the fetus during pregnancy, J. Korean Med. 21 (2000)
40–44.
[28] C.W. Kim, Clinical study for the 37 cases of herbal medicine on pregnancy, J.
Korean Med. 19 (1998) 75–85.
[29] G.S. Kim, S.H. Baek, A case report of hyperemesis gravidarum, J. Korean Obstet.
Gynecol. 10 (1997) 159–168.
[30] S.H. Park, M.S. Chae, N.H. Kim, D.S. Hwang, J.M. Lee, C.H. Lee, et al., 4 Cases of
hyperemesis gravidarum patients treated by herbal medicine and auricular
acupuncture, and safety of these medical interventions, J. Korean Obstet.
Gynecol. 26 (2013) 133–142.
[31] M.Y. Jung, Y.J. Sohn, A clinical case of habitual abortion, J. Korean Obstet.
Gynecol. 18 (2005) 203–212.
[32] H.J. Cho, E.M. Lim, Reccurent miscarriage overcome 14 case series, J. Korean
Obstet. Gynecol. 18 (2005) 159–168.
[33] H.T. Hong, T.G. Lee, A case report of threatened abortion, J. Korean Obstet.
Gynecol. 10 (1997) 117–121.
[34] J.Y. Seo, Y.S. Kim, E.M. Lim, Clinical study on two cases of vaginal bleeding in
early pregnancy, J. Korean Obstet. Gynecol. 16 (2003) 212–219.
[35] S.B. Jang, E.H. Jung, K.H. Choi, D.Y. Yoo, A clinical study on 1 case of infertility
patient with premature ovarian failure, J. Korean Obstet. Gynecol. 27 (2014)
135–142.
[36] J.E. Lee, S.J. Heo, H.J. Cho, H.J. Moon, Obestetic outcomes in 68 pregnant
patients with recurrent pregnancy loss on Oriental treatment and analysis of
factors affercting the success of birth, J. Korean Obstet. Gynecol. 23 (2010)
173–183.
[37] H.S. Wee, J.M. Lee, C.H. Lee, J.H. Cho, J.B. Jang, K.S. Lee, Pregnancy of infertility
with endometriosis after Oriental Medicine treatment diagnosed as a IVF case.
A case report, J. Korean Obstet. Gynecol. 23 (2010) 213–220.
[38] H.J. Cho, E.M. Choi, M.J. Kang, Pregnancy in premature ovarian failure after
oriental medicine treatment. Two cases report, J. Korean Obstet. Gynecol. 17
(2004) 200–208.
[39] K.H. Zhang, H.S. Song, D.K. Lee, B.N. Kim, S.W. Kim, A case report of normal
delivery using Herbmed of twin pregnancy with one fetal death intrauterine, J.
Korean Obstet. Gynecol. 17 (2004) 187–193.
[40] T.H. Kim, S.B. Kim, G.H. Min, C.H. Park, C.M. Choi, B.H. Kang, et al., Clinical study
for the 18cases of the patients with febrile diseases in the pregnancy
prescribed Kungsosankakambang, J. Korean Obstet. Gynecol. 15 (2002)
202–207.
[41] Y.J. Choi, S.H. Jeon, I.S. Lee, Four cases of Bell's palsy patients during pregnancy
treated with Sasang Constitutional Medicine, J. Korean Obstet. Gynecol. 2014
(2014) 1.
[42] J.H. Choi, J.M. Lee, C.H. Lee, J.H. Cho, J.B. Jang, K.S. Lee, Clinical studies on 3 cases
of Bell' s palsy during pregnancy, J. Korean Obstet. Gynecol. 21 (2008) 245–256.
[43] J.A. Lee, H.R. Ban, S.H. Cho, The case study on one case of the Bell's palsy during
the period of pregnancy, J. Korean Obstet. Gynecol. 18 (2005) 186–194.
[44] S. Choi, Y.E. Park, Y.N. Park, K.S. Ryoo, Clinical study on one case of the Bell's
palsy during the period of pregnancy, J. Korean Obstet. Gynecol. 16 (2003)
227–234.
[45] H.G. Ko, C.H. Kim, K.S. Lee, 8 case series of facial palsy during pregnancy, J.
Korean Obstet. Gynecol. 1 (1989) 59–62.
[46] S.M. Shin, H.J. Lim, J.E. Lee, D.Y. Yoo, 2 cases report of the Bell' s palsy occurred
during pregnancy, J. Korean Obstet. Gynecol. 21 (2008) 258–268.[47] K.W. O, I.H. Ryu, J.R. Kim, H.J. Kim, J.A. Kang, S.J. Lee, et al., Case series of low
back pain and pelvic pain caused by trafﬁc accident during pregnancy, J.
Korean Obstet. Gynecol. 22 (2009) 195–205.
[48] S.H. Lee, Y.S. Park, D.C. Kim, Three cases report of patients caused by trafﬁc
accident during early pregnancy, J. Korean Obstet. Gynecol. 23 (2010) 187–195.
[49] Y.J. Choi, Y.J. Kang, I.S. Lee, H.S. Cho, A case report of pruritus gravidarum
diagnosed as Tae-eumin Exterior-Cold-Disease by Cold in the Esophagus, J.
Korean Obstet. Gynecol. 25 (2012) 149–156.
[50] J.Y. Jo, K.S. Park, C.H. Lee, J.B. Jang, K.S. Lee, J.M. Lee, A case report of preterm
labor patient at high risk for preterm delivery treated by combination of herbal
medicine and conventional treatment, J. Korean Obstet. Gynecol. 25 (2012)
200–206.
[51] K.H. Kim, A.R. Jung, E.A. Jung, S.E. Park, Two cases of dermatitis patients during
pregnancy, J. Korean Obstet. Gynecol. 20 (2007) 258–267.
[52] S.J. Lee, C.M. Choi, H.B. Cho, S.B. Kim, K.W. O, T.G. Oh, 4 cases report of
Hyeolheopungyeol type dermatoses gravidarum treated with Sopungsan-
gami, J. Korean Obstet. Gynecol. 20 (2007) 229–237.
[53] S.H. Baek, H.S. Na, H.J. Park, E.A. Jung, S. Choi, The clinical study on one case of
cervical sprain patient due to trafﬁc accident in pregnancy, J. Korean Obstet.
Gynecol. 18 (2005) 207–217.
[54] E.S. Kim, C.H. Lee, J.H. Cho, J.B. Jang, K.S. Lee, The one case of acute dermatitis
patient during the period of pregnancy, J. Korean Obstet. Gynecol. 18 (2005)
195–202.
[55] K.J. Kim, J.H. Cho, J.B. Jang, K.S. Lee, A case report of trigeminal neuralgia
diagnosed weakness during pregnancy, J. Korean Obstet. Gynecol. 18 (2005)
234–241.
[56] S.H. Baek, E.A. Jung, I.Y. Bae, A clinical study on one case of the woman suffered
from both side ﬂank and back pain due to hydronephrosis during pregnancy, J.
Korean Obstet. Gynecol. 17 (2004) 239–249.
[57] Y.S. Park, D.C. Kim, S.H. Baek, 3 cases report of lower limbs edema owing to
pregnancy treated with Gami-ondamtang, J. Korean Obstet. Gynecol.16 (2003)
189–198.
[58] S.H. Jung, J.H. Cho, J.B. Jang, K.S. Lee, The one case of dermatosis gravidarum
patient who has an aspect of bollous pemphigoid of pregnancy, J. Korean
Obstet. Gynecol. 15 (2002) 172–180.
[59] W. Choi, M. Kim, A clinical case report of a tinnitus patient in pregnancy, J.
Korean Oriental Med. Ophthalmol. Otolaryngol. Dermatol. 23 (2010) 218–223.
[60] T. Wei, S. Yang, The case study on one case of the asthma during the period of
pregnancy, Korean J. Oriental Med. Prescr. 14 (2006) 176–183.
[61] M. Kim, Y. Yun, K. Kim, I. Choi, Three cases of atopic dermatitis in pregnant
women successfully treated with Korean medicine, Complement Ther. Med. 21
(2013) 512–516.
[62] B.K. Kim, S.Y. Park, D.S. Jung, W.J. Han, A clinical study about prolonging
pregnancy in patient with pre-eclampsia, J. Med. Gi-Gong 13 (2013) 36–45.
[63] L. Li, P.C. Leung, T.K.H. Chung, C.C. Wang, Systematic review of chinese
medicine for miscarriage during early pregnancy, Evidence-Based
Complementary Altern. Med. 2014 (2014) 1–16.
[64] H.J. Moon, M.J. Kang, Clinical efﬁcacy of oriental medicine in in vitro
fertilization (IVF), J. Korean Obstet. Gynecol. 14 (2001) 127–135.
[65] L. Li, L.Y. Tang, G.C. Man, B.H. Yeung, C.B. Lau, P.C. Leung, et al., Potential
reproductive toxicity of Largehead Atractylodes Rhizome, the most commonly
used Chinese medicine for threatened miscarriage, Hum. Reprod. 26 (2011)
3280–3288.
[66] M.A. Kim, N.H. Yee, J.S. Choi, J.Y. Choi, K. Seo, Prevalence of birth defects in
Korean livebirths, 2005–2006, J. Korean Med. Sci. 27 (2012) 1233–1240.
